KRAS: The 'Undruggable' Target That's Finally Being Drugged

KRAS: The 'Undruggable' Target That's Finally Being Drugged

If your pathology report or oncologist has mentioned a KRAS mutation, you’re not alone. This is one of the most common drivers of cancer, and for decades, it was considered "undruggable." But that story is changing rapidly, and new treatments are offering hope where there was very little before.

What Is KRAS?

KRAS is a gene that acts like a central switch inside your cells. It tells the cell when to grow and when to stop growing. Think of it as the accelerator pedal in a car. When it works normally, it presses down to make the cell divide (when needed) and lifts up to make it stop. This process is tightly controlled.

But when the KRAS gene gets mutated—or damaged—this switch gets stuck in the "ON" position. The accelerator is pressed down permanently. The cell receives non-stop signals to grow and divide, even when it shouldn’t. That uncontrolled growth is a hallmark of cancer.

How a KRAS Mutation Drives Cancer

Normally, KRAS is activated by signals from outside the cell—like a message telling it it’s time to grow. It does its job briefly, then turns off. A mutated KRAS, however, ignores these external signals. It’s always active. Always sending the “grow” command.

This is why KRAS mutations are so powerful. They sit at the center of many critical cell growth pathways. When KRAS is stuck on, it sets off a cascade of signals that lead to tumor formation, survival, and spread.

Which Cancers Are Linked to KRAS Mutations?

KRAS mutations are especially common in some of the most challenging cancers. If you or a loved one has been diagnosed with one of the following, there’s a strong chance a KRAS mutation is involved:

• Pancreatic cancer: Up to 91.8% of pancreatic tumors have a KRAS mutation.
• Colorectal cancer: KRAS mutations appear in about 95.7% of colorectal adenocarcinomas.
• Appendiceal and Ampullary cancers: These rarer cancers also show high rates, at 63.4% and 56.6% respectively.
• Certain ovarian cancers: Low-grade serous ovarian cancer has a KRAS mutation frequency of 40.4%.
• Lung cancer: While not listed in this specific data set, KRAS is also a major driver in non-small cell lung cancer.

This prevalence is why researchers have been so desperate to find a way to target it.

Why KRAS Was Called "Undruggable"

For over 40 years, scientists tried and failed to create a drug that could block mutant KRAS. The protein itself is very smooth, with no obvious pockets or grooves for a drug molecule to latch onto. It was like trying to stop a car with a stuck accelerator by fiddling with the engine, but without any tools that could fit.

This left patients with KRAS-driven cancers with fewer targeted options. Treatment often relied on more general chemotherapy, which can be harder on the body.

The Breakthrough: How KRAS Is Finally Being Drugged

The big turning point came when scientists discovered they could target a specific type of KRAS mutation known as KRAS G12C. This is like finding a tiny, unique lock on that smooth surface that only appears in the mutated version of the protein.

Researchers designed drugs—called covalent inhibitors—that fit perfectly into that lock and jam it. The drug binds permanently to the mutant KRAS protein and prevents it from sending its "grow" signal. It effectively pries your foot off the accelerator.

The first of these drugs, sotorasib (Lumakras), was approved by the FDA in 2021 for certain patients with non-small cell lung cancer with the KRAS G12C mutation. Another drug, adagrasib (Krazati), has also been approved. This was a monumental achievement in cancer medicine.

Clinical trials are now actively exploring these and similar drugs for other cancers driven by KRAS G12C, including colorectal cancer.

What This Means For Your Treatment

1. Get Tested: The most critical step is comprehensive biomarker testing of your tumor. This will tell you exactly what type of mutation you have (e.g., G12C, G12D, G12V). Your treatment options depend entirely on this specific result.
2. Ask About Clinical Trials: The science is moving fast. If you have a KRAS mutation—especially one that isn't G12C—ask your oncologist about clinical trials testing the newest generation of KRAS inhibitors. Researchers are developing drugs for other common KRAS mutations like G12D.
3. Combination Therapies: Often, these new targeted drugs work best when combined with other treatments, like immunotherapy or chemotherapy. Your care team will build a strategy tailored to your cancer’s unique genetic profile.

The Bottom Line

A KRAS mutation is a significant finding, but it is no longer a dead end. It is a target. The narrative has shifted from "undruggable" to "druggable." While the first approved drugs only work for one specific type of KRAS mutation, they have blown the door open for a whole new class of medicines.

Your best path forward is through testing, asking questions, and exploring all options with a team that understands the latest advances in targeting KRAS. There is genuine, science-driven hope on the horizon.